Targeting the checkpoint kinases: chemosensitization versus chemoprotection
- 1 March 2004
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 4 (3), 216-225
- https://doi.org/10.1038/nrc1296
Abstract
No abstract availableKeywords
This publication has 86 references indexed in Scilit:
- Suppression of Tousled-like kinase activity after DNA damage or replication block requires ATM, NBS1 and Chk1Oncogene, 2003
- Questioning the Role of Checkpoint Kinase 2 in the p53 DNA Damage ResponseOnline Journal of Public Health Informatics, 2003
- The Chk2 Tumor Suppressor Is Not Required for p53 Responses in Human Cancer CellsOnline Journal of Public Health Informatics, 2003
- The role of p53 in determining sensitivity to radiotherapyNature Reviews Cancer, 2003
- DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociationNature, 2003
- Activation of mammalian Chk1 during DNA replication arrestThe Journal of cell biology, 2001
- Cell cycle-dependent and ATM-independent expression of human Chk1 kinaseOncogene, 1999
- A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphataseCurrent Biology, 1999
- Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumorsCancer, 1997
- Protection of Normal Tissues from the Cytotoxic Effects of Chemotherapy and Radiation by Amifostine (WR-2721): Preclinical AspectsEuropean Journal of Cancer, 1995